“None of us really can effectively advise our licensees, which is just incredibly frustrating, especially with a ticking clock.”
By Amanda Watford, Stateline
The U.S. Department of Justice’s recent decision to downgrade the drug classification for medical cannabis will help medical marijuana businesses. Companies will be able to claim some federal tax benefits. New research can start up at state universities.
But the broader divide between federal and state marijuana policy remains largely intact, leaving states to navigate a fragmented and still-evolving cannabis landscape with few clear answers about what comes next.
The unprecedented change in April reclassifying medical marijuana from Schedule I to Schedule III means the federal government is acknowledging an accepted healthcare use for cannabis. Recreational marijuana, however, remains a Schedule I drug under federal policy, even though 24 states and the District of Columbia allow recreational cannabis in various forms, from dried flower to vaping oils to processed gummy candies.
The U.S. Drug Enforcement Administration is set to hold its first hearing at the end of June on the possible de-scheduling of marijuana broadly, which would include recreational or adult-use cannabis.
Until then, some experts say little is expected to change for the more than half
Read full article on Marijuana Moment
